Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04527666

Enrollment

Registered

2020-08-26

Start date

2020-10-01

Completion date

2022-09-30

Last updated

2020-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal Varices, JAK2 Mutation, Myeloproliferative Neoplasm

Keywords

portal hypertension, gastroesophageal varices, jak2 mutation, myeloproliferative neoplasm

Brief summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Interventions

DRUGAnticoagulation Agents

Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Male or female patients aged 18-75 * diagnosed as portal hypertension by contrast-enhanced computed tomography * diagnosed as JAK2 positive

Exclusion criteria

* not had portal contrast-enhanced computed tomography * not had JAK2 mutation test * other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors

Design outcomes

Primary

Measure	Time frame	Description
Changes of portal vein thrombosis	1 year	The changes of portal vein thrombosis including progression, disappear or unchanged.

Secondary

Measure	Time frame	Description
The occurrence of variceal bleeding	1 year	The occurrence of variceal bleeding including haematemesis and melena
Overall survival	1 year	Overall survival rate

Contacts

Primary ContactXiaoquan HUANG, Ph.D

huang.xiaoquan@zs-hospital.sh.cn18801733835

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026